Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases

Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases

Purpose Although bevacizumab (BV) increases survival rates when used with chemotherapy (CTX) in patients who have metastatic colorectal cancer (CRC), an increase in wound complications has been observed in patients who undergo surgery while receiving BV. We therefore evaluated whether neoadjuvant BV...

Full description

Saved in:
Bibliographic Details
Main Author: Kesmodel, Susan (author)
Other Authors: Ellis, Lee (author), Lin, E. (author), Chang, George (author), Abdalla, Eddie (author), Kopetz, Scott (author), Vauthey, Jean-Nicolas (author), Rodriguez-Bigas, Miguel (author), Curley, Steven (author), Feig, Barry (author)
Format: article
Published: 2008
Online Access:http://hdl.handle.net/10725/2590
http://dx.doi.org/10.1200/JCO.2008.17.7857
http://jco.ascopubs.org/content/26/32/5254.short
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://hdl.handle.net/10725/2590
http://dx.doi.org/10.1200/JCO.2008.17.7857
http://jco.ascopubs.org/content/26/32/5254.short

Similar Items